Immune enhancement by novel vaccine adjuvants in autoimmune-prone NZB/W F1 mice: Relative efficacy and safety

BMC Immunology

Volumn 12, Issue , 2011, Pages

  Aachoui, Youssef ^a   Ghosh, Swapan K ^a  

^a INDIANA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM POTASSIUM SULFATE; CROSS REACTING ANTIBODY; DOUBLE STRANDED DNA; HAPTEN ANTIBODY; IMMUNOLOGICAL ADJUVANT; IMMUNOSTIMULATING AGENT; PHIS 01; PHIS 03; PHYTANOL; PHYTANYL MANNOSE; SIS H; UNCLASSIFIED DRUG; AUTOANTIBODY; CYTOKINE; DNA; DRUG DERIVATIVE; PHARMACEUTICAL VEHICLES AND ADDITIVES; PHTHALIC ACID; PHTHALIC ACID DERIVATIVE; PHYTOL;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; CROSS REACTION; DRUG EFFICACY; FEMALE; MOUSE; NONHUMAN; ANIMAL; AUTOIMMUNE DISEASE; BAGG ALBINO MOUSE; C57BL MOUSE; COMPARATIVE STUDY; DRUG EFFECT; GENE REARRANGEMENT; GENETIC PREDISPOSITION; GENETICS; HUMAN; HUMORAL IMMUNITY; IMMUNOLOGY; METABOLISM; NEW ZEALAND BLACK MOUSE; SWINE; VACCINATION;

ADJUVANTS, PHARMACEUTIC; ALUM COMPOUNDS; ANIMALS; AUTOANTIBODIES; AUTOIMMUNE DISEASES; CROSS REACTIONS; CYTOKINES; DNA; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNITY, HUMORAL; IMMUNOGLOBULIN CLASS SWITCHING; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED NZB; PHTHALIC ACIDS; PHYTOL; SWINE; VACCINATION;

EID: 80054816241     PISSN: None     EISSN: 14712172     Source Type: Journal    
DOI: 10.1186/1471-2172-12-61     Document Type: Article

References (45)

1. Schijns VE. Immunological concepts of vaccine adjuvant activity. Curr Opin Immunol 2000, 12:456-63. 10.1016/S0952-7915(00)00120-5, 10899018.
2. Harandi AM, Davies G, Olesen OF. Vaccine adjuvants: scientific challenges and strategic initiatives. Expert Rev Vaccines 2009, 8:293-8. 10.1586/14760584.8.3.293, 19249971.
3. Lim SY, Meyer M, Kjonaas RA, Ghosh SK. Phytol-based novel adjuvants in vaccine formulation: 1. assessment of safety and efficacy during stimulation of humoral and cell-mediated immune responses. J Immune Based Ther Vaccines 2006, 4:6. 10.1186/1476-8518-4-6, 1635037, 17074094.
4. Lim SY, Bauermeister A, Kjonaas RA, Ghosh SK. Phytol-based novel adjuvants in vaccine formulation: 2. Assessment of efficacy in the induction of protective immune responses to lethal bacterial infections in mice. J Immune Based Ther Vaccines 2006, 4:5. 10.1186/1476-8518-4-5, 1633728, 17059608.
5. Mackie JT, Atshaves BP, Payne HR, McIntosh AL, Schroeder F, Kier AB. Phytol-induced hepatotoxicity in mice. Toxicol Pathol 2009, 37:201-8. 10.1177/0192623308330789, 2838495, 19188468.
6. Kagoura M, Matsui C, Morohashi M. Phytol is a novel tumor promoter on ICR mouse skin. Jpn J Cancer Res 1999, 90:377-84. 10.1111/j.1349-7006.1999.tb00758.x, 10363574.
7. Aachoui Y, Roy Chowdhury R, Fitch R, Ghosh S. Molecular signatures of phytol-derived immunostimulants in the context of chemokine-cytokine microenvironment and enhanced immune response. Cell. Immunol. 2011, 271:227-38.
8. Aachoui Y, Schulte M, Fitch R, Ghosh S. Synthetic adjuvants for vaccine formulations: Evaluation of new phytol derivatives in induction and persistence of specific immune response. Cell. Immunol. 2011, 271:308-18.
9. Satoh M, Reeves WH. Induction of lupus-associated autoantibodies in BALB/c mice by intraperitoneal injection of pristane. J Exp Med 1994, 180:2341-6. 10.1084/jem.180.6.2341, 2191761, 7964507.
10. Satoh M, Kumar A, Kanwar YS, Reeves WH. Anti-nuclear antibody production and immune-complex glomerulonephritis in BALB/c mice treated with pristane. Proc Natl Acad Sci USA 1995, 92:10934-8. 10.1073/pnas.92.24.10934, 40545, 7479913.
11. Satoh M, Richards HB, Shaheen VM, Yoshida H, Shaw M, Naim JO, Wooley PH, Reeves WH. Widespread susceptibility among inbred mouse strains to the induction of lupus autoantibodies by pristane. Clin Exp Immunol 2000, 121:399-405. 10.1046/j.1365-2249.2000.01276.x, 1905709, 10931159.
12. Kuroda Y, Nacionales DC, Akaogi J, Reeves WH, Satoh M. Autoimmunity induced by adjuvant hydrocarbon oil components of vaccine. Biomed Pharmacother 2004, 58:325-37. 10.1016/j.biopha.2004.04.009, 15194169.
13. Daley WP, Peters SB, Larsen M. Extracellular matrix dynamics in development and regenerative medicine. J Cell Sci 2008, 121:255-264. 10.1242/jcs.006064, 18216330.
14. Crapo PM, Wang Y. Small intestinal submucosa gel as a potential scaffolding material for cardiac tissue engineering. Acta Biomaterialia 2010, 6:2091-2096. 10.1016/j.actbio.2009.10.048, 2862886, 19887120.
15. Badylak S, Kokini K, Tullius B, Simmons-Byrd A, Morff R. Morphologic Study of Small Intestinal Submucosa as a Body Wall Repair Device. The Journal of surgical research 2002, 103:190-202. 10.1006/jsre.2001.6349, 11922734.
16. Cheng EY, Kropp BP. Urologic tissue engineering with small-intestinal submucosa: potential clinical applications. World J Urol 2000, 18:26-30. 10.1007/PL00007071, 10766040.
17. Badylak S, Arnoczky S, Plouhar P, Haut R, Mendenhall V, Clarke R, Horvath C. Naturally occurring extracellular matrix as a scaffold for musculoskeletal repair. Clin Orthop Relat Res 1999, S333-43.
18. Suckow MA, Hall P, Wolter W, Sailes V, Hiles MC. Use of an Extracellular matrix material as a vaccine carrier and adjuvant. Anticancer Research 2008, 28:2529-2534.
19. Lim SY, Ghosh SK. Autoreactive responses to an environmental factor: 1. phthalate induces antibodies exhibiting anti-DNA specificity. Immunology 2003, 110:482-92. 10.1111/j.1365-2567.2003.01765.x, 1783077, 14632646.
20. Lim SY, Ghosh SK. Autoreactive responses to an environmental factor. 2. Phthalate-induced anti-DNA specificity is downregulated by autoreactive cytotoxic T cells. Immunology 2004, 112:94-104. 10.1111/j.1365-2567.2004.01842.x, 1782471, 15096189.
21. Lim SY, Ghosh SK. Autoreactive responses to environmental factors: 3. Mouse strain-specific differences in induction and regulation of anti-DNA antibody responses due to phthalate-isomers. J Autoimmun 2005, 25:33-45. 10.1016/j.jaut.2005.04.002, 15993037.
22. Ghosh SK, Bankert RB. Generation of heavy chain-loss mutants in a B cell hybrid mediated by syngeneic idiotype-specific spleen cells. J Immunol 1984, 133:1677-82.
23. Jellum E, Eldjarn L, K T. Conversion of phytol into dihydrophytol and phytanic acid. Acta Chem Scand 1966, 20:2535-2538.
24. Bendavid A, Burns CJ, Field LD, Hashimoto K, Ridley DD, Sandanayake KR, Wieczorek L. Solution- and solid-phase synthesis of components for tethered bilayer membranes. J Org Chem 2001, 66:3709-16. 10.1021/jo0057147, 11374989.
25. Schmidt RR MJ. Facile Synthesis of α- and β-0-Glycosyl Imidates;. Preparation of Glycosides and Disaccharides'. Angew Chem Int Ed Engl 1980, 19:731-732.
26. Ghosh SK. Phytol-derived immunoadjuvants and their use in vaccine formulations. Us patent Aplication #11/295131
27. Abramoff MD, Magelhaes PJ, Ram SJ. Image Processing with ImageJ. Biophotonics International 2004, 11:36-42.
28. Peng SL, Moslehi J, Craft J. Roles of interferon-gamma and interleukin-4 in murine lupus. J Clin Invest 1997, 99:1936-46. 10.1172/JCI119361, 508018, 9109438.
29. Rothfield NF, Stollar BD. The relation of immunoglobulin class, pattern of anti-nuclear antibody, and complement-fixing antibodies to DNA in sera from patients with systemic lupus erythematosus. J Clin Invest 1967, 46:1785-94. 10.1172/JCI105669, 292929, 4168731.
30. Ebling F, Hahn BH. Restricted subpopulations of DNA antibodies in kidneys of mice with systemic lupus. Comparison of antibodies in serum and renal eluates. Arthritis Rheum 1980, 23:392-403. 10.1002/art.1780230402, 7370058.
31. Boes M, Schmidt T, Linkemann K, Beaudette BC, Marshak-Rothstein A, Chen J. Accelerated development of IgG autoantibodies and autoimmune disease in the absence of secreted IgM. Proc Natl Acad Sci USA 2000, 97:1184-9. 10.1073/pnas.97.3.1184, 15562, 10655505.
32. Kuroda Y, Nacionales DC, Akaogi J, Reeves WH, Satoh M. Autoimmunity induced by adjuvant hydrocarbon oil components of vaccine. Biomedecine & Pharmacotherapy 2004, 58:325-337.
33. Segerer S, Nelson PJ, Schlondroff D. Chemokines, Chemokine Receptors, and Renal Disease: From Basic ScienceTo Pathophysiologic and Therapeutic Studies. Journal of the American Society of Nephrology 2000, 11:152-176.
34. Sallusto F, Baggiolini M. Chemokines and leukocyte traffic. Nat Immunol 2008, 9:949-952. 10.1038/ni.f.214, 18711431.
35. Lema GPD, Maier H, Nieto E, Vielhauer V, Luckow B, Mampaso F, SchlÖndorff D. Chemokine Expression Precedes Inflammatory Cell Infiltration and Chemokine Receptor and Cytokine Expression during the Initiation of Murine Lupus Nephritis. Journal of the American Society of Nephrology 2001, 12:1369-1382.
36. Zoja C, Liu X, Donadelli R, Abbate M, Testa D, Corna D, Taraboletti G, Vecchi A, Dong Q, Rollins B, Bertani T, Remuzzi G. Renal expression of monocyte chemoattractant protein-1 in lupus autoimmune mice. Journal of the American Society of Nephrology 1997, 8:720-729.
37. Tesch GH, Maifert S, Schwarting A, Rollins BJ, Kelley VR. Monocyte Chemoattractant Protein 1-Dependent Leukocytic Infiltrates Are Responsible for Autoimmune Disease in Mrl-Faslpr Mice. The Journal of Experimental Medicine 1999, 190:1813-1824. 10.1084/jem.190.12.1813, 2195716, 10601356.
38. Ishikawa S, Sato T, Abe M, Nagai S, Onai N, Yoneyama H, Zhang Y, Suzuki T, Hashimoto S, Shirai T, et al. Aberrant high expression of B lymphocyte chemokine (BLC/CXCL13) by C11b+CD11c+ dendritic cells in murine lupus and preferential chemotaxis of B1 cells towards BLC. J Exp Med 2001, 193:1393-402. 10.1084/jem.193.12.1393, 2193305, 11413194.
39. Segerer S, Mack M, Regele H, Kerjaschki D, Schlondorff D. Expression of the C-C chemokine receptor 5 in human kidney diseases1. Kidney Int 1999, 56:52-64.
40. Bohle A, Wehrmann M, Bogenschutz O, Batz C, Vogl W, Schmitt H, Muller CA, Muller GA. The long-term prognosis of the primary glomerulonephritides. A morphological and clinical analysis of 1747 cases. Pathol Res Pract 1992, 188:908-24.
41. Segerer S, Nelson PJ, SchlÖndorff D. Chemokines, Chemokine Receptors, and Renal Disease: From Basic ScienceTo Pathophysiologic and Therapeutic Studies. Journal of the American Society of Nephrology 2000, 11:152-176.
42. Satoh M, Kuroda Y, Yoshida H, Behney KM, Mizutani A, Akaogi J, Nacionales DC, Lorenson TD, Rosenbauer RJ, Reeves WH. Induction of lupus autoantibodies by adjuvants. J Autoimmun 2003, 21:1-9. 10.1016/S0896-8411(03)00083-0, 12892730.
43. Heeger PS, Forsthuber T, Shive C, Biekert E, Genain C, Hofstetter HH, Karulin A, Lehmann PV. Revisiting Tolerance Induced by Autoantigen in Incomplete Freund's Adjuvant. The Journal of Immunology 2000, 164:5771-5781.
44. Spatz L, Saenko V, Iliev A, Jones L, Geskin L, Diamond B. Light chain usage in anti-double-stranded DNA B cell subsets: role in cell fate determination. J Exp Med 1997, 185:1317-26. 10.1084/jem.185.7.1317, 2196257, 9104818.
45. Bynoe MS, Spatz L, Diamond B. Characterization of anti-DNA B cells that escape negative selection. Eur J Immunol 1999, 29:1304-13. 10.1002/(SICI)1521-4141(199904)29:04<1304::AID-IMMU1304>3.0.CO;2-6, 10229098.